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Abstract
Introduction: Breast cancer is the most common cancer affecting women. Many patients ultimately progress to metastatic disease and
optimal management of this disease remains a significant therapeutic challenge. Lapatinib, a dual tyrosine kinase inhibitor, is in clinical
development for treatment of this disease. 
Aims: The objective of this article is to review the published evidence for the treatment of metastatic breast cancer with lapatinib, and
assess its therapeutic potential.
Evidence review: Most evidence has appeared in meeting abstract reports of phase I and II studies in healthy volunteers and cancer
patients. Four studies have included patients with exclusively breast cancer. Complete and partial responses and stable disease has
been reported in some patients. Emerging evidence indicates that complete and partial responses can be achieved in some patients
with metastatic breast cancer. Lapatinib appears to be well tolerated in cancer patients and the maximum tolerated dose is in the region
of 1800 mg/day. In addition, it has been used in combination with other cancer treatments. Five ongoing or planned phase II
monotherapy and three phase III combination-therapy studies with lapatinib have been identified. 
Outcomes summary: The phase I and II studies reported to date have provided safety data and preliminary indications regarding
efficacy. There is preliminary evidence that lapatinib can achieve objective response rates of 10–38% in patients with metastatic breast
cancer. Patients with tumors overexpressing ErbB1 and/or ErbB2 are likely to benefit from lapatinib treatment.
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Core evidence proof of concept summary for lapatinib in metastatic breast cancer
Outcome measure Emerging evidence
Efficacy Potential to use as monotherapy, or in combination, in patients with pretreated metastatic breast cancer
Common dose for monotherapy is 1500 mg/day
Response rates Some evidence that objective (complete or partial) responses may occur in 10–38% of patients 
Biomarker expression Partial responses seen in patients with tumors overexpressing ErbB2 (where measured)
Tolerability  Good tolerability with daily administration alone or in combination with paclitaxel or capecitabine 
Maximum tolerated dose is 1800 mg/day in cancer patients 
Once-daily dose regimen better tolerated than twice-daily regimenScope, aims, and objectives
Breast cancer is the most common cancer affecting women and is
one of the leading causes of cancer death. A significant proportion of
patients initially diagnosed with early-stage breast cancer ultimately
progress to metastatic disease. Optimal management of metastatic
breast cancer remains a significant therapeutic challenge. 
Lapatinib (GSK572016) is a novel orally administered dual
tyrosine kinase inhibitor in development for the treatment of solid
tumors. It is currently being evaluated in phase II and phase III
trials in patients with metastatic breast cancer. 
The objective of this review is to evaluate the emerging evidence
for the potential use of lapatinib in the treatment of metastatic
breast cancer. 
Methods
The English language medical literature was reviewed for
relevant articles relating to lapatinib for the treatment of
metastatic or advanced breast cancer. The following databases
were searched on March 22, 2005 using the search terms
“lapatinib OR GW572016” for articles published between
January 1990 and March 2005 (inclusive):
• PubMed, www.ncbi.nlm.nih.gov/entrez
• Database of Abstracts of Reviews of Effectiveness (DARE),
NHS Economic Evaluations Database (NHSEED), Health
Technology Assessment (HTA),
www.york.ac.uk/inst/crd/darehp.htm
• NHS HTA, www.ncchta.org
• National Guidelines Clearinghouse, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• Cochrane Database of Systematic Reviews,
www.cochrane.org
• Clinical Evidence, www.clinicalevidence.com
In addition, the annual scientific sessions from the American
Society of Clinical Oncology (ASCO), San Antonio Breast Cancer
Symposium (SABCS), European Cancer Conference (ECCO), and
European Society of Medical Oncology (ESMO) held between
2002 and 2005 were searched for relevant meeting abstracts.
ClinicalTrials.gov was searched for information on ongoing phase
II and III studies with lapatinib. A total of 22 articles were
identified after animal, in-vitro, or other nonrelevant studies were
excluded. One further article was identified after the search date
and included in the evidence evaluation.
There have been a number of phase I and phase II studies
conducted using lapatinib for the treatment of metastatic breast
cancer. In addition, studies involving patients with a variety of
solid tumors have been included here if results with breast cancer
have been reported. Table 1 summarizes the levels of evidence of
articles identified from the search strategy. No systematic reviews
were identified for the use of lapatinib. In addition, no economic
publications have yet appeared. 
Disease overview
Breast cancer is the most frequently diagnosed nonskin cancer in
women. More than 41000 new cases are diagnosed each year in
the UK, accounting for about a third of all cancers in women. The
lifetime risk for breast cancer in women is one in nine (Cancer
Research UK 2004). During 2004 in the USA approximately
216 000 new cases of invasive breast cancer were predicted to
occur in women and about 40 000 deaths were expected to result
from the disease (ACS 2004). Only lung cancer causes more
cancer-related deaths in women. 
There are a number of risk factors associated with the
development of breast cancer (reviewed in Veronesi et al. 2005).
Age is the strongest risk factor associated with a diagnosis of the
disease; breast cancer is rare in women under 30 years of age but
the risk increases in older women. Other risk factors include a
personal or family history of breast cancer, never having children
or having the first child after 30 years of age, a long menstrual
history (starting early and ending late in life), recent use of
hormone replacement therapy or oral contraception,
postmenopausal obesity, regular alcohol consumption, and
mammographically dense breast tissue. In contrast, the risk is
lowered by breastfeeding, moderate or vigorous physical activity,
and maintenance of a healthy bodyweight. 
Most patients presenting with breast cancer have disease
localized to the breast and axillary lymph nodes and 40–50% of
patients initially diagnosed with early breast cancer may develop
metastatic disease. In addition, about 10% of patients with newly
diagnosed breast cancer will have locally advanced and/or
metastatic disease (Bernard-Marty et al. 2004). The most
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Number of records
Category Full papers Abstracts
Initial search 9 32
records excluded 6 13
records included 3 19
Additional studies identified 10
Level 1 clinical evidence 0 0
Level 2 clinical evidence 10
Level ≥3 clinical evidence 3 10
trials other than RCT 09
case studies 0 0
Economic evidence 00
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 
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common sites of metastatic disease are bone, liver, lungs, skin,
and brain (Mincey & Perez 2004). Fortunately earlier detection
and improved treatment have resulted in decreases in mortality
rates of 2.3% per year from 1990 to 2000 (ACS 2004). Indeed,
since 1990 declining mortality rates have been seen in western
Europe and Australia as well as the Americas as a result of
progress in these activities (Veronesi et al. 2005). Screening for
breast cancer allows for the detection of cancers before they
become palpable. Small tumors are more likely to be early-stage
disease, have a better prognosis, and are more successfully
treated (Tabar et al. 1999). Although earlier detection has
contributed to a decline in rate, metastatic disease now
represents the biggest clinical challenge in managing breast
cancer. Despite progress in this area metastatic breast cancer
remains essentially incurable and the median survival time is
about 2 years after documentation of metastases (Bernard-Marty
et al. 2004). 
Current therapy options 
Patient management following initial suspicion of breast cancer
generally includes confirmation of the diagnosis, evaluation of
stage of disease, and selection of therapy. Breast cancer is
commonly treated by various combinations of surgery, radiation
therapy, chemotherapy, and hormone therapy. Prognosis and
selection of therapy may be influenced by the age and
menopausal status of the patient, stage of the disease,
histologic and nuclear grade of the primary tumor, measures of
proliferative capacity, and status of various prognostic markers
(Simpson et al. 2000).
The current treatment goals for the management of metastatic or
advanced breast cancer are a delay in disease progression,
prolongation of survival, amelioration of symptoms, and
optimizing of quality of life (Veronesi et al. 2005). Several factors
influence the decision regarding treatment choices for patients
with metastatic cancer. These include the patient’s overall
condition (e.g. presence of comorbidities and their performance
status), sites of metastases, previous treatment regimens, and
biologic characteristics of the tumor. In addition, treatment of
specific complications in specific organs is now used routinely.
For example, bisphosphonates can be used to reduce bone pain
and other skeletal events in women with advanced breast cancer
(Veronesi et al. 2005). 
When diagnosed with metastatic breast cancer it is critically
important that the tumor should be tested (ideally from a new
biopsy) for markers [particularly estrogen receptor (ER),
progesterone receptor (PR) and ErbB2] against which therapies
may be targeted (Mincey & Perez 2004). 
Essentially there are three systemic treatment modalities for
advanced breast cancer: endocrine therapy, chemotherapy, and
biologic targeted therapy. Endocrine therapy is considered
appropriate for patients with hormonally responsive tumors
(positive for ER and/or PR) also involving soft tissues or bone and
when the disease is not life threatening. If these criteria are not
met then chemotherapy is the first choice (Mincey & Perez 2004). 
Endocrine therapy has the benefit of combining efficacy and
good quality of life outcomes with low toxicity (Bernard-Marty et
al. 2004). Tamoxifen is recommended for premenopausal
women with advanced disease although the luteinizing
hormone-releasing hormone agonists are another therapeutic
option. The first agents of choice for postmenopausal women
are the aromatase inhibitors as they provide a therapeutic ratio
superior to that of tamoxifen (Bernard-Marty et al. 2004).
Endocrine therapy is mandatory in younger premenopausal
patients with ER-positive tumors. However, treatment needs to
be tailored in this population as most clinical experience has
been gained in older premenopausal women (reviewed in
Dellapasqua et al. 2005). 
Chemotherapy is the only option for women with ER- and ErbB2-
negative, endocrine-resistant disease. The most active drugs are
the anthracyclines and taxanes followed by alkylating agents,
antimetabolites, and vinca alkaloids. Docetaxel remains the
reference agent in metastatic breast cancer (Hamilton &
Hortobagyi 2005). Examples of single-agent response rates for
some of these therapies include 35–50% for vinorelibine, 32–48%
for docetaxel, 30–40% for doxorubicin and epirubicin, and
14–37% for gemcitabine (Hamilton & Hortobagyi 2005). However,
complete responses are rare and disease progression is usually
inevitable, and there is no consensus on the true impact of
chemotherapy on survival and quality of life in patients with
metastatic breast cancer (Bernard-Marty et al. 2004). No single
chemotherapy regimen is best for all patients but with the variety
of options available individualization of care is possible (Mincey &
Perez 2004). 
Biologic targeted therapy is based on molecules implicated in
molecular pathways relevant to the biology of the breast cancer
cell. The target should be measurable in the clinic, and its
measurement should correlate with clinical outcome when the
therapy is administered. It is vital that targeted therapy requires
clinical validation, otherwise it is not targeted therapy (Sledge
2005). Targeted biologic therapies have the advantage of
maximizing efficacy while often reducing toxicity compared with
classical chemotherapeutic agents.
One target for biologic therapy is the ErbB family of receptors,
which consists of four closely related members: ErbB1 (EGFR),
ErbB2 (HER-2), ErbB3 (HER-3), and ErbB4 (HER-4). These
receptors share the common structural features of an
extracellular domain for ligand binding, a single transmembrane
alfa-helix, and an intracellular domain containing regulatory
sequences and tyrosine kinase regulator or receptor. Evidence
suggests that ErbB2 acts mainly as a coreceptor, increasing 
the affinity of ligand binding to the dimeric receptor 
complex. Ligand binding induces dimerization of two 
identical (homodimer) or different (heterodimer) receptors.
Signaling through ErbB2 and ErbB3 requires heterodimerization
as ErbB2 has no known ligand and ErbB3 lacks tyrosine 
kinase activity (although it is a potent activator of this 
enzyme). Stimulation by a specific ligand confers a unique
dimerization profile that is tumor- or tissue-specific (Olayioye 
et al. 2000). 
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plays an important role in the development and subsequent
progression of cancer. Tumors may have truncated or mutated
receptors that confer constitutive activation of the receptor.
Overexpression of ErbB2, triggering homodimeric activation of
kinase activity, is seen in a significant proportion of breast (and
ovarian) cancers where it is associated with poor prognosis
(Olayioye et al. 2000). In addition, ErbB1 is also overexpressed
in up to 30% of primary invasive breast cancers and is
correlated with reduced overall survival, proliferation, and
increased metastatic potential (Nicholson et al. 1990; Tsutsui et
al. 2002). 
At present trastuzumab, targeting ErbB2, is the one biologic agent
approved for the treatment of metastatic breast cancer. The
biologic significance of overexpression of ErbB2 in breast cancer,
and the demonstration that monoclonal antibodies directed
against ErbB2 inhibited malignant transformation in preclinical
models, led to the development of trastuzumab. It is a humanized
antibody composed of an antigen-binding component (from the
murine monoclonal antibody 4D5) combined with human
immunoglobulin G (IgG). Antibodies directed against ErbB2 affect
tumor growth directly by altering the receptors’ signaling
properties and also indirectly by antibody-dependent cell-
mediated toxicity and complement-dependent cytotoxicity
(Sliwkowski et al. 1999). 
Trastuzumab is one of the few agents that has led to an
improvement of overall survival in metastatic breast cancer and
so the evaluation of ErbB2 status has become crucial in
deciding optimal treatment. Several issues surround the clinical
use of trastuzumab, including methodology used to determine
ErbB2 status, optimal administration regimen, risk of drug-
related congestive heart failure, and emergence of resistance.
About 60% of ErbB2 patients do not respond to trastuzumab,
and in those who do respond, median duration of response to
monotherapy has been reported to range from 3.7 to 8.4
months (Norum et al. 2005). Although randomized studies have
not been conducted comparing single-agent trastuzumab with
a combination of trastuzumab and chemotherapy, the
combination is clearly superior to chemotherapy alone. In
addition, preclinical synergy has been demonstrated with
trastuzumab and several chemotherapeutic agents including
carboplatin, cyclophosphamide, docetaxel, and vinorelibine
(Hamilton & Hortobagyi 2005). 
Cooperative activation of different ErbB family members
through heterodimerization may evade the therapeutic efficacy
of inhibition of a single receptor target which, for example, may
in part explain the relatively low response rates with
trastuzumab. Therefore, dual inhibition of both ErbB1 and
ErbB2 appears an attractive therapeutic strategy. Lapatinib is a
potent inhibitor of the tyrosine kinase activity of ErbB1 and
ErbB2 in cells, ErbB-dependent tumor growth in vitro, and in
animal models (Rusnak et al. 2001; Xia et al. 2002). This agent
is in clinical development for the treatment of metastatic breast
cancer. Studies for the treatment of other solid tumors
expressing these markers are also ongoing. 
The optimal management of metastatic breast cancer remains a
significant therapeutic challenge. Single-agent therapy is
frequently used for the management of asymptomatic patients
with metastatic breast cancer. For patients with symptomatic or
more extensive disease combination therapy is often used. No
modern single agent offers a clear survival advantage over
another, and other than ErbB2 and trastuzumab no molecular
marker has been shown to consistently predict responses to any
individual agent (Hamilton & Hortobagyi 2005). In the palliative
setting both tolerability and quality of life issues are of critical
importance. Because of unmet needs (improvements in quality
of life, tolerability issues, and limited response rates) with
existing treatments for metastatic breast cancer lapatinib is one
of about 50 new agents currently being evaluated in clinical
trials (Mincey & Perez 2004). 
Outcomes achieved with lapatinib in clinical
development 
Several studies with lapatinib have included both efficacy and
tolerability outcomes. Efficacy outcomes have been exclusively
disease-orientated (response rates and biomarker expression).
Lapatinib has been evaluated as monotherapy and also in
combination with other therapeutic agents. Four studies have
involved patients with exclusively breast cancer and several
others have enrolled patients with a variety of solid tumors,
including breast cancer. 
Monotherapy
Preliminary evidence from a number of studies indicates objective
responses (complete plus partial responses) to orally
administered lapatinib 1500–1600 mg/day in about 10–38% of
patients with metastatic breast cancer (Table 2). 
Lapatinib 1500 mg/day is being studied in a phase II multicenter
open-label trial in a population of 80 patients with metastatic
breast cancer overexpressing ErbB2. Abstract reports of interim
analysis showed that one complete response, three partial
responses, and 15 instances of stable disease had been
achieved in 41 patients recruited thus far (Blackwell et al.
2004a,b). A total of seven (17%) of these 41 patients remained
progression-free at 6 months. 
EGF10004 is a phase Ib, open-label study of lapatinib in heavily
pretreated metastatic cancer patients with tumors accessible to
biopsy. Outcomes measured in this study include clinical
response at 8 weeks and expression of biomarkers (Dees et al.
2004; Burris et al. 2005; Spector et al. 2005). In this study,
lapatinib 500–1600 mg/day was administered to 67 patients with
a variety of metastatic carcinomas overexpressing ErbB1 and/or
ErbB2. Four partial responses were observed, all in patients with
paclitaxel- and trastuzumab-resistant metastatic breast cancer.
Two of these responses occurred in women with recurrent
inflammatory breast cancer. Disease stabilization (ranging from 8
to 41 weeks) was noted for 23 patients although the number with
breast cancer was not stated. A subset of 33 patients in
EGF10004 participated in an analysis of sequential biopsies.
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Fourteen (42%) of these patients were women with metastatic
breast cancer previously treated with multiple chemotherapeutic
regimens, most in combination with trastuzumab and in some
cases hormonal therapy. Biopsy analysis conducted on the
tumors from the four patients with partial responses showed
markedly elevated levels of activated phospho-ErbB2. In addition,
inhibition of both cyclin D and transforming growth factor-alfa
(TGF-alfa) (an ErbB1 ligand) was also seen in the biopsy samples. 
Biomarker analysis has also been conducted on biopsy 
samples taken from two large phase II studies in metastatic 
breast cancer patients treated with lapatinib and trastuzumab-
containing regimens (Blackwell et al. 2005). Early declines 
in the extracellular domain (ECD) of ErbB2 appear to 
predict a lapatinib response. Responders are likely to 
have an intact ErbB2 ECD and short duration of prior
trastuzumab therapy. 
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3
a Results from the first 41 patients included 1 CR, 3 PR, 
15 SD (the clinical benefit rate, SD+PR, was 22% in the
first 36 patients evaluated for efficacy)
Total response for ≤8 weeks was 46.3% and 12 patients
had ≤16 weeks progression-free survival
LAP (1500 mg/day) 56 patients with metastatic breast
cancer overexpressing ErbB2
(enrolled by May 2004) 
(Study EGF20002)
Blackwell et al. 2004a 
Blackwell et al. 2004b
3 Four PR, all in patients with PAC- and TZM-resistant
metastatic breast cancer
23 patients (with various carcinomas) had SD lasting
8–41 weeks
Four PR occurred, all in breast cancer patents
All patients with PR showed inhibition of the biomarkers
p-ErbB1, cyclin D, and TGF-alfa
SD occurred in 3 breast cancer patients 
Clinical responses occurred in patients who had not
responded to TZM, indicating no crossresistance
LAP (500–1600
mg/day) 
67 patients with a variety of
metastatic carcinomas
overexpressing ErbB1 and/or
ErbB2 
(Study EGF10004)
Burris et al. 2005
Dees et al. 2004 
Burris et al. 2003a
Burris 2004
Spector et al. 2003
Spector et al. 2004 
Spector et al. 2005
3
a 7 of 19 progression-free patients at 16 weeks achieved
an OR (either CR or PR) 
Intact ErbB2 ECD and shorter duration of TZM therapy
are likely predictors of response
LAP (1250–1500
mg/day)
81 patients with metastatic breast
cancer progressing on TZM
(Studies EGF20002 and
EGF20008)
Blackwell et al. 2005
3
a PR in 5 patients, SD (≥8 weeks) in 6 patients, PD in
2 patients 
LAP (1500 mg/day
or 500 mg twice
daily) 
13 evaluable patients with ErbB2
expressing locally advanced or
metastatic breast cancer 
Gomez et al. 2005
3
a One patient with TZM-resistant breast cancer
overexpressing ErbB2 had a PR with LAP 1600 mg/day;
one further breast cancer patient had SD
LAP (900–1800
mg/day)
24 patients with advanced solid
tumors
Minami et al. 2004
3
a One breast cancer patient treated with LAP 1600 mg/day
had SD for 7 months
LAP (175–1800
mg/day, or 900 mg
twice daily)
39 patients with various solid
tumors
(Study EGF10003)
Burris et al. 2003b
Burris 2004
3
a Of 27 evaluable patients there was 1 CR, 5 PR, 10 SD,
and 11 PD
LAP (750–1500
mg/day) plus TZM
(standard regimen)
48 patients with ErbB2
overexpressing metastatic breast
cancer 
Storniolo et al. 2005
3
a Three OR in patients with taxane-resistant metastatic
breast cancer
One breast cancer patient had SD for ≥3 months
LAP (1250–1500
mg/day) plus PAC
(135–225 mg/m
2)
26 patients with solid tumors
(Study EGF10009)
Jones et al. 2003
Jones et al. 2004
3
a Within the 8 breast cancer patients there was 1 CR
(inflammatory breast cancer refractory to TZM and
chemotherapy) and 1 PR 
LAP (1250–1500
mg/day) plus CAP
(1500–2500 mg/m
2)
8 pretreated breast cancer
patients (study included 45
patients in total with advanced
solid tumors)
Schwartz et al. 2004
De Bono et al. 2003
3
a SD for >5 months in 4 patients (2 of whom had
advanced breast cancer) 
LAP (1250–1500
mg/day) plus LET
(2.5 mg/day) 
36 patients with solid tumors
(EGF10030)
Chu et al. 2005 
aAbstract.
CAP, capecitabine; CR, complete response; ECD, extracellular domain; LAP, lapatinib; LET, letrozole; OR, objective response; PAC, paclitaxel; PD, progressive disease; p-ErbB1,
phospho-ErbB1; PR, partial response; SD, stable disease; TGF-alfa, transforming growth factor-alfa; TZM, trastuzumab.
Table 2 | Disease response and biomarker expression achieved with lapatinib in patients with metastatic breast cancer
 Antitumor activity with lapatinib 900–1800 mg/day was reported
in a meeting abstract of a phase I Japanese study in patients with
advanced solid tumors (Minami et al. 2004). Of the two patients
who had partial responses, one recipient of lapatinib 1600 mg/day
had trastuzumab-resistant breast cancer overexpressing ErbB2
and negative for ER and PR expression. One further patient with
breast cancer (and 11 other patients with various tumors) had
stable disease. The authors recommended that phase II studies
using lapatinib up to 1600 mg/day were warranted. 
Lapatinib (1500 mg/day or 500 mg twice daily) has also shown
promising activity as first-line treatment in patients with ErbB2-
positive advanced or metastatic breast cancer (Gomez et al.
2005). Preliminary data from the first 13 patients demonstrated a
partial response in five patients, stable disease (for at least 8
weeks) in six patients with the remaining two patients
experiencing progressive disease. A total enrolment of 130
patients is planned for this study. 
Most of the evidence with lapatinib is in patients overexpressing
ErbB2. However, EGF10003 was a phase I study involving 39
patients with solid tumors independent of ErbB receptor status
(Burris et al. 2003b). Nine patients with a variety of tumors had
stable disease for up to 13 months. Only one of these patients
had breast cancer and had stable disease for 7 months following
treatment with lapatinib at 1600 mg/day (Burris 2004). 
Combination therapy
Patients with metastatic breast cancer are already likely to be
receiving systemic treatment, so the combination of lapatinib
and other therapies is likely to reflect the situation in clinical
practice. Results from a number of studies have shown the
benefit of combining biologic therapy (trastuzumab) with
endocrine therapy or chemotherapy for treating metastatic
breast cancer (Bernard-Marty et al. 2004). To date four
published studies have investigated lapatinib in combination
with other treatments (Table 2). 
Lapatinib combined with the standard weekly dosing of
trastuzumab (4 mg/kg loading dose followed by weekly 2 mg/kg
infusions) has shown promising clinical efficacy in pretreated
patients with ErbB2 overexpressing metastatic breast cancer
(Storniolo et al. 2005). Of 48 treated patients, 27 were evaluable
for response in this phase I study. There was one complete
response (duration 8 months), five partial responses (duration 2–7
months), 10 patients with stable disease (duration 1–5 months),
and 11 patients with progressive disease. 
In a study reported in a meeting abstract, among 45 patients with
advanced solid tumors treated with lapatinib combined with
capecitabine there were eight patients with pretreated breast
cancer (De Bono et al. 2003; Schwartz et al. 2004). Within this
subgroup there was one complete response in a patient with
inflammatory breast cancer refractory to both trastuzumab and
chemotherapy. This tumor overexpressed ErbB2 and had low
levels of thymidlate synthase (a target for capecitabine). In
addition, there was another patient with a partial response. 
Lapatinib combined with paclitaxel was used in a study of 26
cancer patients. In this heterogeneous population there were three
objective responses (i.e. complete or partial responses), all in
patients with taxane-resistant metastatic cancer. One other breast
cancer patient had stable disease for at least 3 months. The
authors noted that a phase III study is planned comparing
paclitaxel 155 mg/m2 every 3 weeks with or without lapatinib
1500 mg/day in women with metastatic cancer (Jones et al. 2004). 
Treatment with lapatinib plus letrozole led to four out of 36 patients
with solid tumors experiencing stable disease for more than 
5 months. Two of these patients had advanced breast cancer, but
the proportion of all the evaluable patients with breast cancer was
not stated (Chu et al. 2005). 
Safety and tolerability 
The safety and tolerability of lapatinib has been determined in
both healthy volunteers and patients with cancer (Table 3). The
maximum tolerated dose in cancer patients has been found to be
1800 mg/day. It has also been determined that single-daily dosing
is better tolerated than twice-daily dosing. 
Safety and pharmacokinetic data from single- and multiple-dose
phase I trials of lapatinib in healthy volunteers have recently
been published (Bence et al. 2005). The results showed that
single doses of lapatinib (ranging from 10 to 250 mg) were well
tolerated and there were no serious adverse events when
compared with placebo. There were 23 adverse events recorded
in a total of 47 administrations of lapatinib and all but one (a
grade 2 headache after lapatinib 25 mg) were grade 1 (all
adverse events were graded by the National Cancer Institute
Common Toxicity Criteria version 2.0). Similarly, multiple doses
of lapatinib were also well tolerated. The most common adverse
event recorded in this study was gastrointestinal discomfort in
the form of bloating, flatulence, and/or gas, occurring in five of
18 subjects receiving lapatinib. In addition, of the 28 adverse
events recorded in subjects receiving either lapatinib or
placebo, five were grade 2 and resolved without treatment; three
volunteers receiving placebo had grade 2 bloating, flatulence
and/or gas, and two subjects (one placebo and one lapatinib
recipient) had a grade 2 elevation of liver function enzymes
which resolved within a week. 
EGF10003, a phase I maximum tolerated dose study, was the first
involving administration of lapatinib to cancer patients (Burris et al.
2003b; Koch et al. 2003; Burris 2004). Preliminary tolerability
results with lapatinib 175–1800 mg/day (given to 40 patients) and
900 mg twice daily (three patients) indicated no grade 3 toxicities
with the daily doses but two cases of grade 3 diarrhea were
reported for the twice-daily regimen (Burris 2004). A maximum
tolerated dose study was also conducted in Japanese patients
with advanced solid tumors (Minami et al. 2004). Groups of six
patients were given one of four daily doses of lapatinib to
determine the maximum tolerated dose, defined as the dose at
which two of six patients had grade 3 toxicities. The maximum
tolerated dose was found to be 1800 mg/day, the highest dose
used in this phase I study. In addition, the tolerability of once-daily
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doses of lapatinib 175–1800 mg was compared with 500, 750, or
900 mg twice daily in 64 patients with advanced solid tumors
(Pandite et al. 2004). Most drug-related adverse events were
reported to be grade 1 with diarrhea being the most frequent (17%
once-daily vs 29% twice-daily dosing). Two patients receiving 900
mg twice daily had grade 3 diarrhea. It was concluded that
lapatinib given once daily was well tolerated at all doses while 500
and 750 mg were better tolerated than 900 mg twice daily. 
The incidence of adverse events was reported for 67 patients with
metastatic carcinomas treated with daily doses of lapatinib
500–1600 mg (Dees et al. 2004; Burris et al. 2005). Five grade 3
drug-related toxicities (gastrointestinal and rash) were reported in
four patients. The most frequent adverse events were transient
grade 1 and 2 diarrhea (30%) and rash (12%). It was stated that
there was no clear dose relationship for these adverse events, but
that lapatinib was well tolerated. 
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2 No serious AEs seen in either study
Single doses of ≤250 mg and multiple doses of ≤175 mg
LAP were well tolerated in healthy subjects
Single-dose study
LAP 10–250 mg or
PLA
Multiple-dose study
LAP 25–175 mg/day
or PLA
16 (single-dose study) and 27
(multiple-dose study) healthy
volunteers 
Bence et al. 2005
3
a Safety results from the first 41 patients showed
prevalence of rash (37%), fatigue (34%) diarrhea (27%),
nausea (24%), anorexia (15%), and vomiting (12%) 
LAP (1500 mg/day) 56 patients with metastatic breast
cancer overexpressing ErbB2
enrolled by May 2004
(EGF20002)
Blackwell et al. 2004a
Blackwell et al. 2004b
3
a Maximum tolerated dose determined as 1800 mg/day LAP (900–1800
mg/day)
24 patients with advanced solid
tumors 
Minami et al. 2004 
3 Common AEs included transient grade 1 and 2 rash
(12%) and diarrhea (30%)
Five grade 3 drug-related toxicities (gastrointestinal and
rash) occurred with four patients
67 patients with a variety of
metastatic carcinomas
overexpressing ErbB1 and/or
ErbB2
Burris et al. 2005
Dees et al. 2004
3
a Grade 1–2 rash, diarrhea, nausea, vomiting, constipation,
fatigue, and anorexia were the most frequent AEs
following daily dosing. Grade 3 toxicity (diarrhea) only
seen with twice-daily dosing
Patients remaining on therapy for >4 months received
LAP ≥1200 mg/day
LAP (175–1800
mg/day, or 900 mg
twice daily)
39 cancer patients
(Study EGF10003)
Koch et al. 2003
Burris et al. 2003b
Burris 2004
3
a Most AEs were grade 1 (75% daily dose vs 71% twice
daily). Diarrhea was the most frequent AE (17% daily dose
vs 29% twice daily). Other AEs included fatigue (16%),
nausea (16%), and rash (9%) with daily dosing; nausea
(11%) and rash (11%) with twice-daily dosing 
1 patient experienced grade 2 cardiac toxicity 
All daily doses were tolerated; 500 and 750 mg twice
daily were better tolerated than 900 mg twice daily
LAP (175–1800
mg/day, or 500,
750, or 900 mg
twice daily)
81 (64 in safety assessment)
patients with advanced solid
tumors
Pandite et al. 2004
3
a The optimally tolerated combination was found to be
PAC 175 mg/m
2 (q3w) plus LAP 1500 mg/day
Grade 4 neutropenia (n=5), grade 3 diarrhea (n=2), grade
3 neuropathy (n=1), and grade 3 arthralgia/myalgia (n=1)
were reported
No clear relationship between peak plasma
concentrations and toxicity
LAP (1250–1500
mg/day) plus PAC
(135–225 mg/m
2)
26 patients with solid tumors
(Study EGF10009)
Jones et al. 2003
Jones et al. 2004
3
a Optimally tolerated combination was LAP 1250 mg/day
with CAP 200 mg/m2 q3w
LAP (1250–1500
mg/day), CAP
(1500–2500 mg/m
2)
45 patients with advanced solid
tumors
Schwartz et al. 2004 
De Bono et al. 2003
3a Optimally tolerated combination was LET 2.5 mg plus
LAP 1500 mg/day 
LAP (1250–1500
mg/day) plus LET
(2.5 mg/day) 
36 patients with solid tumors
(Study EGF10030)
Chu et al. 2005 
aAbstract.
AE, adverse event; CAP, capecitabine; LAP, lapatinib; LET, letrozole; PAC, paclitaxel; PLA, placebo; q3w, every 3 weeks.
Table 3 | Tolerability of lapatinib in healthy volunteers and patients with cancer
 In the ongoing study EGF20002, lapatinib 1500 mg/day is being
used to treat women with trastuzumab-refractory metastatic
breast cancer (Blackwell et al. 2004a,b). For 41 patients with
preliminary safety data there were 14 with grade 3–4 events
including grade 3 rash (n=1), grade 3 fatigue (n=2), and grade 3
diarrhea (n=4). Lapatinib appeared to be well tolerated in this
population. 
Optimally tolerated doses of lapatinib when used in combination
with other treatments have also been determined in phase I
studies with cancer patients. The combination of paclitaxel and
lapatinib was studied at six dose levels in 26 patients (Jones et
al. 2003, 2004). Due to the cumulative neuropathy, and dose-
limiting diarrhea with multiple paclitaxel doses ≥200 mg/m2, the
optimally tolerated regimen was paclitaxel 175 mg/m2 every
3 weeks plus lapatinib 1500 mg/day. In addition, a dose-
escalation study was carried out with lapatinib plus
capecitabine (De Bono et al. 2003; Schwartz et al. 2004). Cancer
patients (n=24) received 14 days’ treatment with capecitabine
(1500–2500 mg/m2) and lapatinib 1250–1500 mg/day every 3
weeks. Dose-limiting toxicities including mucositis, anorexia,
rash, diarrhea, fatigue, and bleeding stomatitis, resulted in an
optimally tolerated regimen of lapatinib 1250 mg plus
capecitabine 2000 mg/m2. In agreement with previous studies
(Dees et al. 2004) it was reported that no clear relationship exists
between peak plasma concentrations and toxicity. Grade 1–2
diarrhea, nausea, rash, and fatigue were the common
nonhematologic toxicities experienced in cancer patients (n=36)
treated with the optimally tolerated regimen of lapatinib
(1500 mg/day) plus letrozole (2.5 mg/day) (Chu et al. 2005). 
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Study design  Patients (n) Endpoint Inclusion criteria Exclusion criteria Reference 
Phase II 
LAP monotherapy
NR, OL, UC, PA, T, MC, MN,
28-day study (Study
EGF103009)
Unknown Change in biomarkers from biopsies Disease progression after
anthracycline-containing
regimen
Major surgery in preceding 
2 weeks
Anon. 2005
LAP (1500 mg once daily and
500 mg twice daily)
monotherapy
R, OL, UC, PA, T, MC, MN,
28-day study (Study
EGF20009)
Unknown  Efficacy and tolerability Histologically confirmed
invasive breast cancer with
incurable IIIb or IIIc with T4
lesions 
Any prior therapy  Anon. 2005
LAP (1500 mg/day)
monotherapy
T, OL, MC
(Study EGF20002)
80 Response rate
Tumor tissue and serum biomarker
expression
Trastuzumab-refractory
metastatic breast cancer
overexpressing ErbB2
Not known  Blackwell
et al. 2004a
LAP (1500 mg/day)
monotherapy 
T, OL, MC
160  Safety and efficacy in ErbB2-
positive and ErbB2-negative groups
Metastatic breast cancer  Not known  Burstein et
al. 2004
LAP
T, MC
(Study CDR0000398179)
Unknown  CNS response rate assessed by MRI ErbB2 overexpressing
invasive breast cancer with
CNS metastases
No concurrent anticancer
biologic or immunotherapy
Anon. 2005
Phase III
CAP ± LAP
R, OL, AC, PA, T
(Study 100151)
Unknown  Safety and efficacy Metastatic breast cancer
overexpressing ErbB2
Severe cardiac disease Anon. 2005
LET ± LAP 
T, R, DB, PC, PA, MC, MN
(Study EGF30008)
Unknown  Efficacy and tolerability  Stage IIIb, IIIc with T4 lesion,
or IV breast cancer
Prior therapy for advanced
or metastatic breast cancer
Anon. 2005
PAC ± LAP
T, R, DB, PC, PA, MC, MN
(Study EGF30001)
Unknown  Efficacy and safety  Tumor tissue available for
testing 
Prior therapy for advanced
or metastatic breast cancer
Anon. 2005
AC, active control; CAP, capecitabine; CNS, central nervous system; DB, double blind; LAP, lapatinib; LET, letrozole; MC, multicenter; MN, multinational; MRI, magnetic resonance imaging; NR,
nonrandomized; OL, open label; PA, parallel assignment; PAC, paclitaxel; PC, placebo controlled; PLA, placebo; R, randomized; T, treatment; UC, uncontrolled.
Table 4 | Ongoing or planned phase II and phase III studies with lapatinib for the treatment of metastatic breast cancer
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Clinical development 
Ongoing and future phase II and III studies with lapatinib for the
treatment of metastatic breast cancer are shown in Table 4. There
are five phase II studies all using lapatinib monotherapy. One trial
will investigate the safety and efficacy of lapatinib in 160 patients
with ErbB2 expressing and nonexpressing tumors. 
There are three phase III randomized studies planned in patients
with metastatic breast cancer. All these studies involve
capecitabine, letrozole, or paclitaxel alone compared with the
respective combination with lapatinib. Two studies are double
blind and placebo-controlled while the third (capecitabine plus
lapatinib) is open label. 
Outcomes from all these future studies will be crucial in
confirming the potential benefit of lapatinib for the treatment of
metastatic breast cancer. 
Resource utilization
At present optimal treatment of metastatic breast cancer remains
a significant therapeutic challenge. Many patients will have been
treated with other regimens and resistance to some of these
therapies may have developed, limiting the choice of other
therapeutic options. A treatment which can affect nonresistant
targets with good tolerability and improved disease- and patient-
orientated outcomes would have significant impact on disease
management for metastatic breast cancer. 
With pressure increasing on all healthcare budgets significant
resources may need to be allocated to finance new therapies.
When considering metastatic breast cancer there is competition
for these resources from allocation to prevention, primary therapy
or palliative care. Therefore it is important to determine effects on
health with costs of new treatment. Recently an analysis of the
cost effectiveness of trastuzumab has been conducted as this
agent has imposed a significant burden on healthcare budgets
worldwide (Norum et al. 2005). Results from this analysis showed
that the drug was associated with between 0.3 and 0.7 life years
gained at a median cost per patient of €44 196, yielding costs per
life year saved in the range of €63 137–162 417 depending on
survival benefit and discount rate employed. Clearly the costs per
life year gained are very high and many healthcare systems will
have difficulty in accepting this high cost regimen as standard
(Norum et al. 2005). Factors that may change this conclusion
include reductions in the cost of the drug, altering the dosing
regimen, and improvements in survival data. Therefore, the
generation of favorable pharmacoeconomic data is vitally
important for any new treatment in this therapy area.
Patient group/population
Lapatinib is designed to interact with both ErbB2 and ErbB1.
Patients overexpressing these markers on tumors are most likely
to demonstrate greatest benefit from treatment with lapatinib.
Therefore, the ability to biopsy the tumor and confirmation of the
presence of these markers is an important step. However, it is
interesting to note that some patients lacking tumor marker
expression can respond to targeted therapy. Cetuximab targets
ErbB1 and is active in metastatic colorectal cancer, yet it has been
reported recently that colorectal cancer patients with 
ErbB1-negative tumors also have the potential to respond to
cetuximab therapy (Chung et al. 2005). One reason for this is that
analysis of ErbB1 by current immunohistochemical techniques
does not appear to have predictive value and so exclusion of
patients from treatment based on their apparent ErbB1 tumor
status may not be warranted (Chung et al. 2005). Therefore,
whether patients with metastatic breast cancer with ErbB2 and/or
ErbB1 negative tumors (both determined by
immunohistochemistry) respond to lapatinib remains to be
determined.
To date, the patient populations in which lapatinib has been
evaluated have included groups that have tumors overexpressing
ErbB2 and/or ErbB1 or have been heavily pretreated with other
therapeutic agents. Using lapatinib in patients with metastatic
breast cancer in the phase I and phase II studies has resulted in
positive disease-orientated outcomes including response rates,
disease progression, and biomarkers. 
It is likely that lapatinib will be evaluated initially in larger studies
involving these patient populations as they would be expected to
benefit most from this targeted therapy. Involving larger
populations may give the opportunity to determine patient-
oriented outcomes including quality of life measures. 
Clinical potential
A number of meeting abstracts of completed and ongoing studies
have provided preliminary evidence of the achievement of
objective responses (range 10–38%) and stable disease in
patients with advanced or metastatic breast cancer. There have
also been reports of the effect of lapatinib on expression of tumor
markers from biopsies. In a preliminary study, partial responses
with lapatinib all occurred in patients with ErbB2-expressing
breast cancers. In addition, lapatinib inhibited expression of cyclin
D and TGF-alfa expression in tumors from these patients (Spector
et al. 2005). 
Lapatinib appears to be well tolerated in cancer patients and the
maximum tolerated dose is in the region of 1800 mg/day. Optimal
doses of lapatinib have been lower than this when used in
combination with other agents (e.g. trastuzumab, letrozole, paclitaxel,
or capecitabine). The most frequent adverse events reported with
lapatinib have been rash and diarrhea typically of grade 1 or 2, but
cases of grade 3 or 4 have been reported.
Health-related quality of life outcomes may be a measure that can
be explored if other outcomes with lapatinib show promise. Over
the past 10 years many new promising agents have been
introduced and have led to studies in which survival benefits have
been sought for metastatic breast cancer. The metastatic setting
has given rise to the largest single group of quality of life trials in
breast cancer. Unfortunately, health-related quality of life
outcomes in these studies have generally provided little additional
Lapatinib | proof of concept review
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outcomes, including toxicity (Goodwin et al. 2003). Therefore, any
new treatment for metastatic breast cancer that shows benefits in
quality of life outcomes is likely to be an advantage compared
with existing therapy. 
Preliminary evidence suggests that the best results with lapatinib
will be gained in patients overexpressing the target markers ErbB2
and/or ErbB1. Thus it will be possible to target these patients most
likely to benefit from treatment. At present metastatic breast
cancer is associated with a poor prognosis, so reports that
lapatinib (as monotherapy or in combination with other agents) has
achieved complete and partial responses in some patients is
encouraging and suggests that it could have an impact in treating
this disease.
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